NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its quarterly earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.85) by $0.04. The biopharmaceutical company earned $26.02 million during the quarter, compared to analyst estimates of $33.13 million. Agios Pharmaceuticals had a negative return on equity of 70.07% and a negative net margin of 356.42%. The firm's quarterly revenue was up 71.2% on a year-over-year basis. During the same period last year, the company posted ($1.63) EPS. View Agios Pharmaceuticals' Earnings History.

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Agios Pharmaceuticals.

13 Wall Street analysts have issued 1-year price targets for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $80.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $65.50 in the next year. This suggests a possible upside of 23.5% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

Media coverage about AGIO stock has been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Agios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN), Dr.Reddy's Laboratories (RDY), Horizon Therapeutics (HZNP) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), bluebird bio (BLUE), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and NVIDIA (NVDA).

Agios Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.27%), Wealthstreet Investment Advisors LLC (0.06%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), NEXT Financial Group Inc (0.01%) and Steward Partners Investment Advisory LLC (0.00%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Steward Partners Investment Advisory LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

AGIO stock was acquired by a variety of institutional investors in the last quarter, including Wealthstreet Investment Advisors LLC, NEXT Financial Group Inc and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, David Scadden and Jacqualyn A Fouse. View Insider Buying and Selling for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $53.03.

Agios Pharmaceuticals has a market capitalization of $3.12 billion and generates $94.39 million in revenue each year. The biopharmaceutical company earns $-346,020,000.00 in net income (profit) each year or ($6.03) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.

The official website for Agios Pharmaceuticals is http://www.agios.com/.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]